Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;54 Suppl 1(Suppl 1):i61-8.
doi: 10.1093/jrr/rrt071.

Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy

Affiliations

Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy

Daniel Habermehl et al. J Radiat Res. 2013 Jul.

Abstract

Modern radiotherapy (RT) techniques are widely used in the irradiation of moving organs. A crucial step in ensuring the correct position of a target structure directly before or during treatment is daily image guidance by computed tomography (CT) or X-ray radiography (image-guided radiotherapy, IGRT). Therefore, combinations of modern irradiation devices and imaging, such as on-board imaging (OBI) with X-rays, or in-room CT such as the tomotherapy system, have been developed. Moreover, combinations of linear accelerators and in-room CT-scanners have been designed. IGRT is of special interest in hypofractionated and radiosurgical treatments where high single doses are applied in the proximity of critical organs at risk. Radiographically visible markers in or in close proximity to the target structure may help to reproduce the position during RT and could therefore be used as external surrogates for motion monitoring. Criteria sought for fiducial markers are (i) visibility in the radiologic modalities involved in radiotherapeutic treatment planning and image guidance, such as CT and kilovoltage (kV) OBI), (ii) low production of imaging artifacts, and (iii) low perturbation of the therapeutic dose to the target volume. Photon interaction with interstitial markers has been shown to be not as important as in particle therapy, where interaction of the particle beam, especially with metal markers, can have a significant impact on treatment. This applies especially with a scanned ion beam. Recently we commenced patient recruitment at our institution within the PROMETHEUS trial, which evaluates a hypofractionation regime, starting with 4 x 10 Gy (RBE), for patients with hepatocellular carcinoma. The aim of this work is, therefore, to evaluate potential implantable fiducial markers for enabling precise patient and thus organ positioning in scanned ion beams. To transfer existing knowledge of marker application from photon to particle therapy, we used a range of commercially available markers of different forms and sizes, consisting of carbon and gold materials, and evaluated them for their potential use in the clinical setup with scanned ion beams at our institution. All markers were implanted in a standardized Alderson phantom and were examined using CT scans and orthogonal kV OBI in our clinical routine protocol. Impact on beam perturbation downstream of the markers in the plateau region of a spread-out Bragg peak (SOBP) was estimated by using radiographic films for clinical proton and carbon ion beams of high and low energies. All tested markers achieved good visibility in CT and kV OBI. Disturbances due to artifacts and dose perturbation were highest in the arbitrarily folded gold and the thickest gold marker, but especially low in the carbon marker. Dose perturbation was highest in the arbitrarily folded gold marker. In summary, the analyzed markers offer promising potential for identifying target structures in our treatment setup at HIT and will soon be used in clinical routine. However, a careful choice of marker, depending on the tumor localization and irradiation strategy, will need to be made.

Keywords: carbon ion therapy; fiducial marker; liver tumors; moving organs; raster-scanning technique.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Rectangular box filled with (manufactured) gelatin solution, in which different markers are inserted. Setup for CT scan under standardized conditions (left); box from different views (middle and right).
Fig. 2.
Fig. 2.
Sagittal plane of markers in gelatine solution, from top to bottom: Visicoil: 0.35 x 20 mm; Visicoil: 0.75 x 20 mm; Visicoil: 1.1 x 20 mm; Gold Anchor: 0.27 x 20 mm, Beammarks: 1.2 x 5 mm; Gold Anchor: 0.27 x 20 mm.
Fig. 3.
Fig. 3.
CT scan of different markers in gelatin solution. Front section (a) containing three different sized Visicoil markers (sizes from top to bottom: 0.35 x 20 mm, 0.75 x 20 mm, 1.1 x 20 mm). Back section (b) containing Gold Anchor marker (0.27 x 20 mm) in first and last position and Beammarks (1.2 x 5 mm).
Fig. 4.
Fig. 4.
Three markers were placed in the Alderson phantom, Visicoil (0.35 x 20 mm), Beammarks (1.2 x 5 mm) and the Carbon marker (1 x 3 mm). On the left upper parts maximal and minimal HU (Hounsfield Units) values of the marker surrounding regions are presented.
Fig. 5.
Fig. 5.
Orthogonal on-board kilovoltage imaging radiographs (OBI). Posterior-anterior (left) and lateral (right) view.
Fig. 6.
Fig. 6.
Digitally reconstructed radiographs (DRRs) of the previous CT scan (see Figs 4 and 5). Marker positions: 1 = Visicoil: 0.35 x 20 mm, 2 = Beammarks: 1.2 x 5 mm, 3 = Carbon marker, 1 x 3 mm.
Fig. 7.
Fig. 7.
Gray value of film irradiation with 150.42 MeV/u carbon ions of Visicoil 0.75mm (upper left), Visicoil 1.1mm (upper right) and Beammarks (lower left) marker and the relative gray value of the two Visicoil markers.

References

    1. Combs SE, Schulz-Ertner D, Herfarth KK, et al. Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions. Chirurg. 2006;77:1126–32. - PubMed
    1. Combs SE, Ellerbrock M, Haberer T, et al. Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol. 2010;49:1132–40. - PubMed
    1. Combs SE, Jakel O, Haberer T, et al. Particle therapy at the Heidelberg Ion Therapy Center (HIT) – Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother Oncol. 2010;95:41–4. - PubMed
    1. Combs SE, Habermehl D, Ganten T, et al. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011;11:67. - PMC - PubMed
    1. Habermehl D, Debus J, Ganten T, et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma – feasibility and clinical response. Radiat Oncol. 2013;8:59. - PMC - PubMed

Publication types